NEWS & PRESS RELEASES

NeuroPhage’s GAIM Technology Chosen as ‘Top Project to Watch’ for the Therapeutic Area Partnerships Conference

Read More

NeuroPhage Appoints Industry Veteran Franz Hefti, PhD, President/COO

Dr. Hefti to Lead All Clinical Development Efforts and Strategic Initiatives

Read More

NeuroPhage Discovers GAIM-changing Molecules to Combat Alzheimer’s Disease and Other Neurodegenerative Disorders

Research Published in the Journal of Molecular Biology

Read More

NeuroPhage, Inc. Raises $17 Million In Series D Financing

Funds Will Advance Novel Approach for Treatment of Alzheimer’s Disease and Other Diseases of Protein Aggregation

Read More

NeuroPhage Awarded Second Grant from Michael J. Fox Foundation for Parkinson’s Disease Research

Novel Approach to Target Disease-driving Misfolded Proteins

Read More

NeuroPhage to Participate in World’s First G8 Dementia Summit

Inaugural Effort to Unite World Dignitaries, Scientific Leaders and Finance Executives in Fight Against Dementia

Read More

Neurophage, Inc. Raises $6.4 Million In Additional Financing

After Successful Pre-IND Meeting, Company On Track to Advance Lead Compound NPT002 into Clinical Trials for Alzheimer’s Disease in 2014

Funds Will Accelerate Development of Novel 2nd Generation Fusion Proteins for Treating Neurodegenerative Disorders

John F. Dee Named Chairman, and Kenneth A. Buckfire Joins as Director

Read More

Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc.

Read More

NeuroPhage Reports Beneficial Effects of its Drug Candidate in a Pre-clinical Study of Parkinson’s Disease Funded by The Michael J. Fox Foundation

Read More

NeuroPhage extends Series B to $21.4M

Read More

NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinson’s Disease Research

Read More

NeuroPhage Selected as Top 10 CNS Biotech Company at the Upcoming 6th Annual Therapeutics Area Partnerships Conference

Read More

NeuroPhage Pharmaceuticals closes $12.4M Series B round

Read More

NeuroPhage Raises a $7 Million Series A Financing to Develop a Unique Disease-Modifying Approach to Treating Alzheimer’s and Other Neurodegenerative Disorders

Read More

Dr. Beka Solomon Named to Scientific American’s SciAm 50 Leading Innovators

Read More